This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.

Practical steps 

Your local Pfizer representative/Healthcare Partnership Manager can provide you with guidance on how to initiate NGENLA for your patients. Access guidance on how to contact us here.

Consider NGENLA for:

Newly diagnosed paediatric Growth Hormone Deficiency (pGHD) patients

NGENLA is indicated for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of Growth Hormone (GH). The recommended dose is 0.66 mg/kg body weight administered once weekly by subcutaneous injection.​​​​​​​1​​​​

Current pGHD patients who are currently on daily GH

Consider NGENLA for your pGHD patients aged 3 years or older who are currently on daily GH treatment, and may benefit from once-weekly treatment. These may include:

• Patients who prefer a less frequent injection schedule
• Patients currently on a daily GH, who are transitioning to injecting themselves.

For patients switching from daily growth hormone, therapy with NGENLA may be initiated at a dose of 0.66mg/kg/week on the day following their last daily growth hormone injection.​​​​​​​1
​​​​

Once-weekly NGENLA may deliver a treatment experience favoured by patients and caregivers​​​​​​​2

NGENLA delivered a favoured treatment experience for patients and caregivers in a phase 3 crossover study versus daily Genotropin (somatropin) in pGHD, based on lower treatment burden as shown by less life interference, using a range of parameters.

Life interference parameter overall mean scores where patients and caregivers favoured once weekly NGENLA (95% CI) after 12 weeks vs. once daily Genotropin included: willingness to continue treatment, impact on daily activities, caregiver & family life interference and convenience & ease of the injection schedule.

For safety & efficacy data click here.

Study Design
​​​​​​​
Patients and caregivers (N=87) reported improved (lower) Life Interference total score after 12 weeks of once-weekly NGENLA treatment compared to once-daily GH.1,2 Phase 3, randomised, open-label, 2-period, crossover, multicentre study assessing patient perception of treatment burden with the use of NGENLA once weekly versus Genotropin once daily in children 3 to <18 years of age with GH deficiency.1,2
Data are based on patient/caregiver recall following each 12-week treatment period and at the end of the study. Caregivers completed the assessment for children under 8 years of age.2
† Based on Patient Global Impression Severity-Impact on Daily Activities.​​​​​​​2

​​​​​​​

Explore more

Access data on the efficacy and safety profile of NGENLA.

Efficacy and Safety

Learn more about how NGENLA is stored, re​​​​​​​comm​​​​​​​ended dosing, and administration.

Dosing and Storage
References: 

1. ​​NGENLA Summary of Product Characteristics for Great Britain: https://www.medicines.org.uk/emc/search?q=ngenla & Northern Ireland: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=4319e9d0-5396-4363-8dcb-bc72051b39da&type=smpc
​​​​​​​2. Maniatis AK, Carakushansky M, Galcheva S, et al. Perception of treatment burden with once weekly Somatrogon vs once daily Genotropin in pediatric patients with growth hormone deficiency: results from a randomized phase 3 study. Poster 6895 presented at: Annual Meeting of the Endocrine Society [virtual]; March 20-23, 2021.
​​​​​​​​​​​​​​
PP-NGE-GBR-0038. May 2022.

Access the document to support initiation of NGENLA.

NGENLA Formulary Pack

The NGENLA team are here to support you with any queries. Find out how you can get in touch.

Contact Us

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?